MBK faces fresh scrutiny over Osstem Implant restructuring

MBK Partners is facing renewed public scrutiny over its restructuring strategy at Osstem Implant, the nation’s largest dental implant manufacturer. The controversy follows the ongoing challenges at Homeplus, another company in MBK’s portfolio, which is currently undergoing court-supervised rehabilitation due to financial distress. Reports indicate that Osstem Implant has implemented a restructuring plan that has led to employee layoffs and forced reassignments, raising concerns among workers and industry observers. According to local media, Osstem Implant has been conducting a restructuring process in which certain employees are being asked to take on different roles within the company. Those unable to transition into new positions are reportedly placed on hold until alternative assignments become available. Employees allege that this approach amounts to a form of forced attrition, especially given that the company had already reduced its workforce by approximately 20 percent in the previous year as part of broader cost-cutting measures. The company has refuted claims that the current restructuring is part of a larger effort to eliminate staff, stating instead that it is a routine job reassignment initiative designed to enhance operational efficiency and adapt to shifting global market demands. In a statement, Osstem Implant noted that it is offering limited numbers of employees specialized training to support transitions related to the company’s strategic business adjustments. This situation has sparked fears that Osstem Implant might follow a similar path to Homeplus, which has been under court supervision since its financial difficulties began to escalate. Homeplus, once a dominant force in the retail sector, is now grappling with severe liquidity issues and has become a focal point for critics examining MBK Partners’ investment strategies and corporate governance practices. MBK Partners acquired a controlling stake in Osstem Implant in 2023, purchasing 96.1 percent of the shares for around 2.5 trillion won ($1.7 billion). This transaction was conducted in collaboration with Unison Capital Korea, a prominent private equity firm based in Japan. The decision to invest came during a period of turmoil for Osstem Implant, which was dealing with the aftermath of an embezzlement scandal, misleading business reports, and a product recall issued by Chinese authorities. Over the past few years, Osstem Implant has encountered increasing pressures, primarily stemming from declining earnings and challenges in its operations within China. The company’s consolidated operating profit dropped significantly, falling to 80 billion won last year compared to 160 billion won in the preceding year. Despite these financial setbacks, dividend payments have risen substantially, reaching 100.1 billion won last year, marking a sharp increase from 8.6 billion won in 2021 and 3.2 billion won in 2022. Additional dividends totaling 39.2 billion won were distributed in March of this year. MBK Partners has maintained that it does not exert direct control over Osstem Implant’s internal management decisions. Instead, the firm emphasized that it operates as a shareholder rather than an owner, leaving such matters to the discretion of the company’s leadership team. This stance comes amid growing calls for greater transparency and accountability regarding how private equity firms manage their investments, particularly in light of the ongoing struggles at both Osstem Implant and Homeplus.